Phase
Condition
Lupus
Psoriatic Arthritis
Joint Injuries
Treatment
Apremilast
Clinical Study ID
Ages 5-18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Informed consent / assent obtained
Must have completed Week 52 on treatment on core study
Age and sex specific body mass index (BMI) no lower in range than the 5th percentileon Centers for Disease Control (CDC growth chart)
Willing to adhere to study visit schedule and protocol requirements
Must have acceptable benefit/risk for continued treatment with apremilast
Exclusion
Exclusion Criteria:
Answer "yes" to any question on C-SSRS at Week 52 visit of core study
Scheduled surgery or other interventions that would interrupt study participation
Female participants of childbearing potential unwilling to use protocol specifiedmethod of contraception during treatment and for 30 days after last dose
Female participants planning to become pregnant while on study through 30 days afterlast dose
Female participants of childbearing potential with positive pregnancy test at Week 0
Known sensitivity to any products to be administered during dosing
Not likely to be available to complete all protocol-required study visits
Study Design
Connect with a study center
General Hospital of Thessaloniki Ippokrateio
Thessaloniki, 54642
GreeceActive - Recruiting
Meir Medical Center
Kfar Saba, 4428164
IsraelActive - Recruiting
Hospital Universitari i Politecnic La Fe
Valencia, Comunidad Valenciana 46026
SpainActive - Recruiting
Hospital Universitario Ramon y Cajal
Madrid, 28034
SpainActive - Recruiting
Hacettepe Universitesi Tip Fakultesi Hastanesi
Ankara, 06100
TurkeyActive - Recruiting
Istanbul Universitesi Cerrahpasa Tip Fakultesi
Istanbul, 34098
TurkeyActive - Recruiting
Umraniye Egitim ve Arastirma Hastanesi
Istanbul, 34764
TurkeyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.